Omega collaboration will leverage the company™s platform to develop an epigenomic controller as part of a new approach to obesity managementCellarity collaboration will build upon initial work and...
Cellarity to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Cellarity Named a Top Place to Work for 2023 by The Boston Globe
Cellarity Announces Partnership with Chan Zuckerberg Initiative to Advance New Machine Learning Algorithms for Single-Cell Analysis
Cellarity Recognized as a 2023 Prix Galien USA Nominee for Best Startup
SOMERVILLE, Mass.--(BUSINESS WIRE)--Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company’s Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem.
Cellarity Strengthens Executive Leadership Team
Flagship-founded Cellarity has hauled in $121 million in new series C funds as the biotech continues to push its cell behavior therapies toward the clinic.
SOMERVILLE, Mass.--(BUSINESS WIRE)--Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding raised to date to $274 million. In addition to participation by Flagship Pioneering and other Series B investors, four new investors participated, including Kyowa Kirin Co. Ltd. and Hanwha Impact Partners. The proceeds of the financing will be used to grow Cellarity’s talent base, strengthen its platform, and advance its pipeline toward the clinic.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Sandra Horning, M.D., to the Company’s Board of Directors. As former Chief Medical Officer and Global Head of Product Development of Roche, Dr. Horning brings extensive experience and expertise in successfully advancing novel medicines to patients for a wide range of diseases and is widely recognized for her outstanding work as a drug developer, translational researcher, patient advocate, and respected mentor.